Heat shock proteins (HSPs) in non-alcoholic fatty liver disease (NAFLD): from molecular mechanisms to therapeutic avenues

被引:1
|
作者
Nie, Zhenwang [1 ]
Xiao, Congshu [1 ]
Wang, Yingzi [2 ]
Li, Rongkuan [1 ]
Zhao, Fangcheng [1 ]
机构
[1] Dalian Med Univ, Dept Infect Dis, Affiliated Hosp 2, Dalian, Peoples R China
[2] Dalian Med Univ, Int Med Dept, Hosp 2, Dalian, Peoples R China
基金
英国科研创新办公室;
关键词
HSP60; HSP70; HSP90; GRP78; NAFLD; Molecular mechanisms; Therapeutic strategies; ENDOPLASMIC-RETICULUM-STRESS; LIPID-ACCUMULATION; MOUSE MODEL; HEPATOCYTES; INHIBITION; EXPRESSION; PATHWAYS; CELLS;
D O I
10.1186/s40364-024-00664-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-alcoholic fatty liver disease (NAFLD), a spectrum of liver conditions characterized by fat accumulation without excessive alcohol consumption, represents a significant global health burden. The intricate molecular landscape underlying NAFLD pathogenesis involves lipid handling, inflammation, oxidative stress, and mitochondrial dysfunction, with endoplasmic reticulum (ER) stress emerging as a key contributor. ER stress triggers the unfolded protein response (UPR), impacting hepatic steatosis in NAFLD and contributing to inflammation, fibrosis, and progression to NASH and eventually hepatocellular carcinoma (HCC). Heat shock proteins (HSPs), including small HSPs such as HSP20 and HSP27, HSP60, HSP70, GRP78, and HSP90, are integral to cellular stress responses. They aid in protein folding, prevent aggregation, and facilitate degradation, thus mitigating cellular damage under stress conditions. In NAFLD, aberrant HSP expression and function contribute to disease pathogenesis. Understanding the specific roles of HSP subtypes in NAFLD offers insights into potential therapeutic interventions. This review discusses the involvement of HSPs in NAFLD pathophysiology and highlights their therapeutic potential. By elucidating the molecular mechanisms underlying HSP-mediated protection in NAFLD, this article aims to pave the way for the development of targeted therapies for this prevalent liver disorder.
引用
收藏
页数:28
相关论文
共 50 条
  • [21] What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?
    Huber, Yvonne
    Galle, Peter R.
    Schattenberg, Joern M.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (01): : 68 - 73
  • [22] Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar?
    Longato, Lisa
    FIBROGENESIS & TISSUE REPAIR, 2013, 6
  • [23] Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
    Ipsen, David Hojland
    Lykkesfeldt, Jens
    Tveden-Nyborg, Pernille
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2018, 75 (18) : 3313 - 3327
  • [24] Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease
    Teng, Tieshan
    Qiu, Shuai
    Zhao, Yiming
    Zhao, Siyuan
    Sun, Dequan
    Hou, Lingzhu
    Li, Yihang
    Zhou, Ke
    Yu, Xixi
    Yang, Changyong
    Li, Yanzhang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
  • [25] Curative role of natural PPARγ agonist in non-alcoholic fatty liver disease (NAFLD)
    Singh, Swati
    Kumar, Anit
    Gupta, Suruchi
    Agrawal, Rohini
    TISSUE BARRIERS, 2024, 12 (03):
  • [26] Natural products in non-alcoholic fatty liver disease (NAFLD): Novel lead discovery for drug development
    Wang, Lu
    Yan, Yonghuan
    Wu, Linfang
    Peng, Jinyong
    PHARMACOLOGICAL RESEARCH, 2023, 196
  • [27] Long non-coding RNAs as modulators and therapeutic targets in non-alcoholic fatty liver disease (NAFLD)
    Tao, Qing
    Xie, Jing
    Wu, Yongkang
    Jin, Yong
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2024, 47 (05): : 506 - 516
  • [28] Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
    Changez, Mah I. Kan
    Mubeen, Maryam
    Zehra, Monezahe
    Samnani, Inara
    Rasool, Aniqa Abdul
    Mohan, Anmol
    Ul Wara, Um
    Tejwaney, Usha
    Kumar, Vikash
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2023, 51 (09)
  • [29] Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
    Burra, Patrizia
    Bizzaro, Debora
    Gonta, Anna
    Shalaby, Sarah
    Gambato, Martina
    Morelli, Maria Cristina
    Trapani, Silvia
    Floreani, Annarosa
    Marra, Fabio
    Brunetto, Maurizia Rossana
    Taliani, Gloria
    Villa, Erica
    LIVER INTERNATIONAL, 2021, 41 (08) : 1713 - 1733
  • [30] Beyond the liver in patients with non-alcoholic fatty liver disease (NAFLD)-cause for concern?
    Armstrong, Matthew J.
    Haydon, Geoffrey
    Syn, Wing-Kin
    HEPATOBILIARY SURGERY AND NUTRITION, 2018, 7 (02) : 138 - 142